|1.||Jordan, V Craig: 30 articles (07/2013 - 01/2002)|
|2.||Komm, Barry S: 18 articles (09/2015 - 09/2005)|
|3.||Thatcher, Gregory R J: 15 articles (05/2014 - 10/2003)|
|4.||Jordan, V C: 14 articles (01/2007 - 01/2000)|
|5.||Bolton, Judy L: 13 articles (05/2014 - 10/2003)|
|6.||Gennari, Luigi: 12 articles (04/2012 - 04/2004)|
|7.||McDonnell, Donald P: 10 articles (11/2015 - 07/2002)|
|8.||Vogel, Victor G: 10 articles (01/2015 - 03/2004)|
|9.||Mirkin, Sebastian: 8 articles (08/2015 - 11/2013)|
|10.||Wickerham, D Lawrence: 8 articles (01/2015 - 01/2005)|
|1.||Breast Neoplasms (Breast Cancer)
03/01/2012 - "The SERMs have good long-term safety, including protective effects against breast cancer. "
10/01/2002 - "This metabolic monitoring can thus serve to evaluate the efficacy of new selective estrogen receptor modulators and may be further extended to improve diagnosis and prognosis of breast cancer."
11/15/2015 - "Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast Cancer."
01/01/2015 - "Multiple, randomized clinical trials have shown both the efficacy and safety of SERMs in reducing the risk of breast cancer. "
11/01/2013 - "Impact of SERM adherence on treatment effect: International Breast Cancer Study Group Trials 13-93 and 14-93."
03/01/2010 - "This result may suggest that SERM is also effective for male osteoporosis."
01/01/2010 - "With its increased efficacy on the prevention of nonvertebral fractures than current available SERMs and its positive effects on the vagina, this new compound may represent an alternative and cost-effective therapy for osteoporosis in postmenopausal women."
05/31/2011 - "SERM improved BMD and endothelial function in elderly postmenopausal women with osteoporosis who had received HRT, and these effects were comparable to or slightly stronger than those of HRT. "
04/01/2010 - "To evaluate a Phase III trial of a new SERM, arzoxefine, for prevention of osteoporosis in younger postmenopausal women. "
01/15/2016 - "We have reported that the carborane compound BE360 is a novel selective estrogen receptor modulator and new therapy option for osteoporosis. "
01/01/2008 - "It is clear from three randomised trials that SERMs prevent ERalpha+ tumors only in women at increased risk and at population risk of BC entered into these trials. "
06/01/2007 - "In all studies, average tumor volumes in SERM-treated animals declined over the course of treatment. "
10/01/2006 - "For the treatment studies, mice with tumors were fed combinations of a SERM and 268 for 4 weeks. "
06/01/2015 - "Future research may focus on identifying new SERMs for endocrine-resistant and endocrine-responsive cancers and post-menopausal symptoms."
07/01/2014 - "We propose that combined therapies with an ERβ agonist and an inhibitor of autophagy may provide the basis for a novel approach to the treatment of SERM/SERD-resistant breast cancers."
05/01/2010 - "Promising results have been observed with the targeted development of newer and more tissue-specific SERMs, many of which are under investigation for postmenopausal osteoporosis. "
03/01/2010 - "More precise molecular mechanisms of the effect of SERM, especially in tissue/cell type specificity, may help to investigate new SERM, which is more specific and effective to treat post-menopausal osteoporosis."
01/01/2007 - "Animal studies and early clinical studies suggest effects in the bone similar to other SERMs with prevention of postmenopausal bone loss. "
03/01/2012 - "Several selective estrogen receptor modulators are in clinical development for postmenopausal osteoporosis. "
02/01/2012 - "EMAS clinical guide: selective estrogen receptor modulators for postmenopausal osteoporosis."
|5.||Leiomyoma (Uterine Fibroids)
01/01/2005 - "In light of therapeutic efficacy and few adverse effects, SERM and SPRM may hold promise as novel treatment modalities for leiomyoma. "
07/01/2000 - "Preclinical evidence for therapeutic efficacy of selective estrogen receptor modulators for uterine leiomyoma."
12/01/2001 - "This antagonist activity in the uterine myometrium suggests that SERMs may be useful in the treatment of uterine leiomyoma."
01/01/2012 - "Further studies are required to establish evidence of benefit of SERMs in treating women with uterine fibroids. "
01/01/2012 - "There is no consistent evidence from the limited number of studies that SERMs reduce the size of fibroids or improve clinical outcomes. "
|1.||Selective Estrogen Receptor Modulators (SERM)
|7.||tartrate salt cis- 1R- (4'- pyrrolidinoethoxyphenyl)- 2S- phenyl- 6- hydroxy- 1,2,3,4- tetrahydronaphthalene (Lasofoxifene)
|2.||Hormone Replacement Therapy (Therapy, Hormone Replacement)
|3.||Drug Therapy (Chemotherapy)
|4.||Estrogen Replacement Therapy
|5.||Heterologous Transplantation (Xenotransplantation)